| Literature DB >> 35377074 |
Mathias Granqvist1,2, Pontus Hedberg3,4, Pontus Nauclér3,4, Anders Enocson5,6.
Abstract
BACKGROUND: SARS-CoV-2 has had an extensive influence on orthopaedic surgery practice and has been associated with an increased risk of mortality. There is limited evidence of how this pertains to acute orthopaedic surgery with inpatient care.Entities:
Keywords: 30-day mortality; COVID-19; Fracture; Orthopaedic surgery; SARS-CoV-2
Year: 2022 PMID: 35377074 PMCID: PMC8943350 DOI: 10.1007/s00590-022-03226-x
Source DB: PubMed Journal: Eur J Orthop Surg Traumatol ISSN: 1633-8065
Fig. 1Study flow chart. Flow chart of hospitalizations with orthopaedic procedures performed. aSee Table S1 for included orthopaedic procedures and diagnoses. bDefined as occurrence of positive SARS-CoV-2 PCR-tests 7 days before to 7 days after an orthopaedic procedure
Baseline characteristics and orthopaedic procedures in patients with and without perioperative SARS-CoV-2 infection
| Characteristic | Perioperative SARS-CoV-2 | ||
|---|---|---|---|
| Yes ( | No ( | ||
| Female sex, | 86 (60) | 3254 (65) | 0.254 |
| Age, median (IQR) | 83 (74–89) | 77 (62–86) | < 0.001 |
| Age category, | |||
| 18–29 | 4 (3) | 189 (4) | < 0.001 |
| 30–44 | 6 (4) | 331 (7) | |
| 45–59 | 9 (6) | 592 (12) | |
| 60–74 | 21 (15) | 1125 (22) | |
| ≥75 | 104 (72) | 2793 (56) | |
| Nursing home residency, | 33 (23) | 633 (13) | < 0.001 |
| Previous co-morbidities, | |||
| Cancer | 26 (18) | 833 (17) | 0.816 |
| Cerebrovascular disease | 19 (13) | 563 (11) | 0.538 |
| Chronic kidney disease | 27 (19) | 489 (10) | 0.001 |
| Diabetes mellitus (type 1 or 2) | 26 (18) | 736 (15) | 0.306 |
| Heart disease | 63 (44) | 1,534 (31) | 0.001 |
| Immunosuppression | 53 (37) | 1,385 (28) | 0.019 |
| Liver disease | 7 (5) | 123 (2) | 0.120 |
| Lung disease | 29 (20) | 981 (19) | 0.934 |
| Neurological disease | 70 (49) | 1,888 (38) | 0.009 |
| Obesity | 7 (5) | 207 (4) | 0.817 |
| Substance use disorder | 11 (8) | 473 (9) | 0.567 |
| No. co-morbidities, median (IQR) | 2 (1–3) | 2 (0–3) | < 0.001 |
| No. co-morbidities, | |||
| None | 24 (17) | 1280 (25) | < 0.001 |
| 1–2 | 61 (42) | 2206 (44) | |
| ≥ 3 | 59 (41) | 1544 (31) | |
| COVID-19 wave, | |||
| First wave | 66 (46) | 1923 (38) | < 0.001 |
| Between first and second wave | 5 (4) | 759 (15) | |
| Second wave | 63 (44) | 1648 (33) | |
| After second wave | 10 (7) | 700 (14) | |
| Length of stay before orthopaedic procedure, median (IQR) | 1 (1–2) | 1 (0–2) | 0.038 |
| Procedure type, | |||
| Elbow, forearm | 1 (1) | 200 (4) | 0.002 |
| Foot, ankle | 15 (10) | 819 (16) | |
| Hip, femur, pelvis | 106 (74) | 2906 (58) | |
| Knee, lower leg | 4 (3) | 392 (8) | |
| Shoulder, arm | 6 (4) | 354 (7) | |
| Spinal | 0 (0) | 35 (1) | |
| Wrist, hand | 2 (1) | 101 (2) | |
| Multiple procedure types | 10 (7) | 223 (4) | |
Mortality and length of stay after orthopaedic procedures in patients with and without perioperative SARS-CoV-2 infection
| Outcome variable | Perioperative SARS-CoV-2 | Unadjusted ratio (95% CI) a | Adjusted ratio (95% CI)a,b | |
|---|---|---|---|---|
| Yes | No | |||
| Main analysis, cohort size | 144 | 5,030 | ||
| Mortality, 30-day, | 32 (22) | 267 (5) | 5.10 (3.33–7.61) | 4.19 (2.67–6.43) |
| Length of stay after surgery, median (IQR) | 13 (6–21) | 7 (2–13) | 0.47 (0.40–0.55) | 0.49 (0.41–0.59) |
| First wave of the COVID-19 pandemic, cohort size | 66 | 1923 | ||
| Mortality, 30-day, | 17 (26) | 107 (6) | 5.89 (3.20–10.38) | 5.69 (2.94–10.66) |
| Length of stay after surgery, median (IQR) | 13 (7–21) | 7 (2–13) | 0.46 (0.37–0.56) | 0.45 (0.34–0.60) |
| Second wave of the COVID-19 pandemic, cohort size | 63 | 1648 | ||
| Mortality, 30-day, | 14 (22) | 90 (6) | 4.95 (2.55–9.07) | 3.78 (1.87–7.31) |
| Length of stay after surgery, median (IQR) | 13 (7–22) | 7 (2–13) | 0.45 (0.35–0.57) | 0.52 (0.41–0.67) |
| Hip, femur or pelvic surgery, cohort size n | 106 | 2906 | ||
| Mortality, 30-day, | 29 (27) | 243 (8) | 4.13 (2.60–6.38) | 4.07 (2.53–6.41) |
| Length of stay after surgery, median (IQR) | 13 (6–20) | 10 (5–15) | 0.50 (0.40–0.62) | 0.50 (0.39–0.63) |
aMortality was analysed by logistic regression, length of stay was analysed by Fine and Gray models
bAdjusted for age (< 65 years vs ≥ 65 years), sex, procedure type, hospital where first procedure was performed and no. co-morbidities. For the sensitivity analysis including only hip, femur or pelvic surgery, procedure type was excluded from the adjusted model
Fig. 2Mortality and length of stay after surgery in patients with and without perioperative SARS-CoV-2 infection. a Unadjusted Kaplan–Meier curves and risk tables for 30-day mortality in patients with and without perioperative SARS-CoV-2 infection. b Cumuative risk (incidence) of hospital discharge alive in patients with and without perioperative SARS-CoV-2 infection